FibroGen announced first patient enrolled in Pamrevlumab clinical trial in patients hospitalized in Italy with severe COVID-19

,

On Jun. 8, 2020, FibroGen announced the initiation of an open-label, randomized, parallel-arm study investigating the efficacy and safety of pamrevlumab versus standard of care in patients with severe coronavirus 2019 (COVID-19) infection at Catholic University of the Sacred Heart in Rome, Italy.

Tags:


Source: FibroGen
Credit: